Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
1
Expiration
Jan 19, 2029
DTE
822d
Moneyness
OTM
Intrinsic
$0.00
IBRX 1 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 20, 2026 | 31d | $0.10 | -62.96% | 1 | 7 |
| Jan 15, 2027 | 87d | $0.05 | +66.67% | 2 | 215 |
| Mar 19, 2027 | 150d | — | — | 0 | 0 |
| Apr 16, 2027 | 178d | — | — | 0 | 0 |
| May 21, 2027 | 213d | — | — | 0 | 0 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | — | — | 0 | 0 |
| Jan 21, 2028 | 458d | $0.15 | -68.09% | 1 | 50 |
| Mar 17, 2028 | 514d | $0.05 | +0.00% | 2 | 0 |
| Jan 19, 2029 | 822d | — | — | 0 | 0 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.